GlassScriptPhysician profile
Shaun Robert Spinks
NPI 1255545752
$3,081.21
in general payments reported to CMS, 2019-2025
27 companies · $1,111 in 2025
The $1,111 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2021: $434 · 2022: $287 · 2023: $299 · 2024: $438 · 2025: $1,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $753.82 | 2021-2025 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $574.17 | 2019-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $302.34 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $247.43 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $201.98 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $186.14 | 2024-2025 | Caplyta |
| Amgen INC. | $113.43 | 2021-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.00 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $95.22 | 2022-2023 | |
| Pfizer INC. | $80.76 | 2019-2025 | |
| Exact Sciences Corporation | $55.18 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $50.17 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $46.24 | 2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $30.49 | 2019-2021 | |
| Genentech USA, INC. | $28.67 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $23.67 | 2019 | |
| Abbott Laboratories | $22.82 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.62 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.57 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.63 | 2025 | Xifaxan |
| Alfasigma USA, INC. | $16.27 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.90 | 2021 | |
| Assertio Therapeutics, INC. | $14.38 | 2019 | |
| Astellas Pharma US INC | $14.37 | 2019 | |
| Merck Sharp & Dohme LLC | $13.02 | 2021 | |
| Scilex Pharmaceuticals INC. | $11.55 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaun Spinks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.